A patient with chronic spontaneous urticaria (CSU) received treatment with the monoclonal antibody omalizumab, which resulted in significant clinical improvement but repeatedly triggered severe anaphylactic reactions. These occurred both after administration o... ...

请注册登录后继续浏览